Leukotriene B5 (LTB5)

Leukotriene B5 is a lipid mediator formed by the 5-lipoxygenase metabolism of eicosapentaenoic acid (EPA)[1][5][7]. Functionally, LTB5 participates in inflammatory signaling but is substantially less potent than Leukotriene B4 (LTB4) in stimulating chemotaxis, lysosomal enzyme release, and platelet aggregation[1][3][5][7]. LTB5 exerts its effects by acting on the same high-affinity leukotriene receptors as LTB4, generally BLT1 and BLT2, and is part of a broader class of eicosanoids involved in immune regulation, vasoconstriction, and vascular permeability[4][7]. Increased endogenous production of LTB5 occurs after EPA supplementation[7], and it is associated with reduced inflammatory responses compared to LTB4.\n\nIf structural or receptor-based target information is sought, it is recommended to search for leukotriene receptors (e.g., BLT1, CysLT1) rather than the leukotriene molecules themselves.

Other names

LTB55S,12S-dihydroxy-6Z,8E,14Z,17Z-eicosapentaenoic acid

Not applicable for LTB5 as a target. For drugs targeting leukotriene signaling, mechanisms include inhibition of leukotriene biosynthesis (e.g. zileuton), antagonism of leukotriene receptors (e.g. montelukast, zafirlukast—these do not target LTB5 directly but may modulate its effects via BLT or CysLT receptors)